Avalon Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:48 pm

Quick Insight

Avalon Technologies Ltd, based in Chennai, currently trades at a price of 844 with a market capitalization of 5,621 Cr. The company's P/E ratio stands at 70.3, indicating a relatively high valuation, while its ROE and ROCE are at 11.0% and 13.4% respectively. With an OPM of 9% and a net profit of 63 Cr, Avalon Technologies shows moderate profitability. The company's reserves amount to 598 Cr, while borrowings stand at ₹180 Cr, resulting in a comfortable ICR of 7.90x. However, the high P/BV ratio of 8.20x suggests a premium valuation. Investors should closely monitor Avalon's operational efficiency and growth prospects to assess its long-term performance.

Competitors of Avalon Technologies Ltd

All Competitor Stocks of Avalon Technologies Ltd

Quarterly Result

Last Updated: August 19, 2025, 10:55 pm

Below is a detailed analysis of the quarterly data for Avalon Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 323.00 Cr.. The value appears to be declining and may need further review. It has decreased from 343.00 Cr. (Mar 2025) to 323.00 Cr., marking a decrease of 20.00 Cr..
• For Expenses, as of Jun 2025, the value is 293.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 301.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 8.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 11.00 Cr..
• For OPM %, as of Jun 2025, the value is 9.00%. The value appears to be declining and may need further review. It has decreased from 12.00% (Mar 2025) to 9.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 14.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 10.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.14. The value appears to be declining and may need further review. It has decreased from 3.67 (Mar 2025) to 2.14, marking a decrease of 1.53.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:45 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:47 pm

Below is a detailed analysis of the balance sheet data for Avalon Technologies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
• For Reserves, as of Mar 2025, the value is 598.00 Cr.. The value appears strong and on an upward trend. It has increased from 534.00 Cr. (Mar 2024) to 598.00 Cr., marking an increase of 64.00 Cr..
• For Borrowings, as of Mar 2025, the value is 180.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 209.00 Cr. (Mar 2024) to 180.00 Cr., marking a decrease of 29.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 248.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 173.00 Cr. (Mar 2024) to 248.00 Cr., marking an increase of 75.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,040.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 929.00 Cr. (Mar 2024) to 1,040.00 Cr., marking an increase of 111.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 185.00 Cr.. The value appears strong and on an upward trend. It has increased from 147.00 Cr. (Mar 2024) to 185.00 Cr., marking an increase of 38.00 Cr..
• For CWIP, as of Mar 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 10.00 Cr..
• For Investments, as of Mar 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 75.00 Cr. (Mar 2024) to 35.00 Cr., marking a decrease of 40.00 Cr..
• For Other Assets, as of Mar 2025, the value is 810.00 Cr.. The value appears strong and on an upward trend. It has increased from 687.00 Cr. (Mar 2024) to 810.00 Cr., marking an increase of 123.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,040.00 Cr.. The value appears strong and on an upward trend. It has increased from 929.00 Cr. (Mar 2024) to 1,040.00 Cr., marking an increase of 111.00 Cr..

Notably, the Reserves (598.00 Cr.) exceed the Borrowings (180.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Avalon Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 9.62. This value is within the healthy range. It has increased from 4.29 (Mar 24) to 9.62, marking an increase of 5.33.
• For Diluted EPS (Rs.), as of Mar 25, the value is 9.48. This value is within the healthy range. It has increased from 4.19 (Mar 24) to 9.48, marking an increase of 5.29.
• For Cash EPS (Rs.), as of Mar 25, the value is 13.91. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 13.91, marking an increase of 6.17.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 92.44. It has increased from 83.29 (Mar 24) to 92.44, marking an increase of 9.15.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 92.44. It has increased from 83.29 (Mar 24) to 92.44, marking an increase of 9.15.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 165.99. It has increased from 131.96 (Mar 24) to 165.99, marking an increase of 34.03.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 19.95. This value is within the healthy range. It has increased from 11.77 (Mar 24) to 19.95, marking an increase of 8.18.
• For PBIT / Share (Rs.), as of Mar 25, the value is 15.63. This value is within the healthy range. It has increased from 8.29 (Mar 24) to 15.63, marking an increase of 7.34.
• For PBT / Share (Rs.), as of Mar 25, the value is 13.11. This value is within the healthy range. It has increased from 5.79 (Mar 24) to 13.11, marking an increase of 7.32.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 9.59. This value is within the healthy range. It has increased from 4.26 (Mar 24) to 9.59, marking an increase of 5.33.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.59. This value is within the healthy range. It has increased from 4.26 (Mar 24) to 9.59, marking an increase of 5.33.
• For PBDIT Margin (%), as of Mar 25, the value is 12.01. This value is within the healthy range. It has increased from 8.92 (Mar 24) to 12.01, marking an increase of 3.09.
• For PBIT Margin (%), as of Mar 25, the value is 9.41. This value is below the healthy minimum of 10. It has increased from 6.27 (Mar 24) to 9.41, marking an increase of 3.14.
• For PBT Margin (%), as of Mar 25, the value is 7.89. This value is below the healthy minimum of 10. It has increased from 4.38 (Mar 24) to 7.89, marking an increase of 3.51.
• For Net Profit Margin (%), as of Mar 25, the value is 5.77. This value is within the healthy range. It has increased from 3.22 (Mar 24) to 5.77, marking an increase of 2.55.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.77. This value is below the healthy minimum of 8. It has increased from 3.22 (Mar 24) to 5.77, marking an increase of 2.55.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.37. This value is below the healthy minimum of 15. It has increased from 5.11 (Mar 24) to 10.37, marking an increase of 5.26.
• For Return on Capital Employeed (%), as of Mar 25, the value is 15.40. This value is within the healthy range. It has increased from 8.37 (Mar 24) to 15.40, marking an increase of 7.03.
• For Return On Assets (%), as of Mar 25, the value is 6.10. This value is within the healthy range. It has increased from 3.00 (Mar 24) to 6.10, marking an increase of 3.10.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.03, marking a decrease of 0.06.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.29 (Mar 24) to 0.23, marking a decrease of 0.06.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has increased from 0.82 (Mar 24) to 1.11, marking an increase of 0.29.
• For Current Ratio (X), as of Mar 25, the value is 2.22. This value is within the healthy range. It has decreased from 2.53 (Mar 24) to 2.22, marking a decrease of 0.31.
• For Quick Ratio (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.30, marking a decrease of 0.10.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 4. It has increased from 1.74 (Mar 24) to 2.20, marking an increase of 0.46.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 7.90. This value is within the healthy range. It has increased from 4.72 (Mar 24) to 7.90, marking an increase of 3.18.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.80. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 4.80, marking an increase of 2.09.
• For Enterprise Value (Cr.), as of Mar 25, the value is 5,057.00. It has increased from 3,300.31 (Mar 24) to 5,057.00, marking an increase of 1,756.69.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.61. This value exceeds the healthy maximum of 3. It has increased from 3.81 (Mar 24) to 4.61, marking an increase of 0.80.
• For EV / EBITDA (X), as of Mar 25, the value is 38.31. This value exceeds the healthy maximum of 15. It has decreased from 42.66 (Mar 24) to 38.31, marking a decrease of 4.35.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.57. This value exceeds the healthy maximum of 3. It has increased from 3.74 (Mar 24) to 4.57, marking an increase of 0.83.
• For Price / BV (X), as of Mar 25, the value is 8.20. This value exceeds the healthy maximum of 3. It has increased from 5.92 (Mar 24) to 8.20, marking an increase of 2.28.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.57. This value exceeds the healthy maximum of 3. It has increased from 3.74 (Mar 24) to 4.57, marking an increase of 0.83.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness